(Reuters) – AstraZeneca’s COVID-19 vaccine sales more than tripled to $894 million in the second quarter from the previous three months but shaved off 1 U.S. cent from earnings, and the drugmaker updated its 2021 forecasts on Thursday to include sales from its Alexion unit.
(Reporting by Pushkala Aripaka in Bengaluru and Alistair Smout in London)
